dc.contributor.author | Chan, HLY | |
dc.contributor.author | Messinger, D | |
dc.contributor.author | Papatheodoridis, GV | |
dc.contributor.author | Cornberg, M | |
dc.contributor.author | Xie, Q | |
dc.contributor.author | Piratvisuth, T | |
dc.contributor.author | Ren, H | |
dc.contributor.author | Kennedy, PT | |
dc.contributor.author | Thompson, A | |
dc.contributor.author | Caputo, A | |
dc.contributor.author | Bakalos, G | |
dc.contributor.author | Pavlovic, V | |
dc.contributor.author | Lampertico, P | |
dc.date.accessioned | 2019-02-22T11:53:59Z | |
dc.date.available | 2019-02-22T11:53:59Z | |
dc.date.issued | 2018-06-29 | |
dc.identifier.citation | Chan HLY, Messinger D, Papatheodoridis GV, et al. A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2018;48:547–555. https://doi.org/10.1111/apt.14862 | en_US |
dc.identifier.issn | 0269-2813 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/55501 | |
dc.description.abstract | Background
Peginterferon induces off‐treatment responses in approximately one‐third of patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B.
Aim:
To develop an easy‐to‐use baseline prediction score to identify hepatitis B virus (HBV) genotype B‐/C‐infected HBeAg‐positive Asian patients likely to respond to peginterferon alfa‐2a.
Methods:
Generalised additive models, multiple logistic regression (MLR) analysis and internal validation methods were applied to data from 647 HBeAg‐positive patients from China, Hong Kong and Taiwan to develop a scoring system to predict response 24 weeks after completing a 48‐week course of peginterferon alfa‐2a.
Results:
Five baseline factors (age, sex, alanine aminotransferase ratio, hepatitis B surface antigen (HBsAg) level and HBV DNA level) were retained in the final MLR for HBeAg seroconversion and used to develop a scoring system from 0 to 7. Among patients with scores of 0‐1, 2‐3, 4 or ≥5, HBeAg seroconversion was achieved in 6.4% (6/94), 23.0% (61/265), 36.4% (67/184) and 54.8% (57/104), respectively, and a combined response (HBeAg seroconversion plus HBV DNA <2000 IU/mL) in 5.3% (5/94), 12.8% (34/265), 25.0% (46/184) and 36.5% (38/104), respectively. Among patients with scores of 0‐1, 2‐3, 4 or ≥5, 57.0% (53/93), 12.3% (31/253), 3.4% (6/178) and 1.0% (1/100) had HBsAg ≥20 000 IU/mL at treatment Week 12; only 3/91 (3.3%) with HBsAg ≥20 000 IU/mL experienced a combined response at 24 weeks post‐treatment (negative predictive value = 97% [88/91]).
Conclusion:
A pre‐treatment scoring system using readily available baseline characteristics identifies HBeAg‐positive Asian patients likely to experience sustained HBeAg seroconversion after treatment with peginterferon alfa‐2a.
© 2018 John Wiley & Sons Ltd | en_US |
dc.description.sponsorship | F. Hoffmann‐La Roche Ltd | en_US |
dc.format.extent | 547 - 555 | |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | |
dc.title | A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1111/apt.14862 | |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000441233600005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.declined | 2019-02-19T12:27:40.564+0000 | |
pubs.issue | 5 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 48 | en_US |
dcterms.dateAccepted | 2018-06-29 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |